Welcome to our dedicated page for Avicanna news (Ticker: AVCNF), a resource for investors and traders seeking the latest updates and insights on Avicanna stock.
Avicanna Inc. operates as a commercial-stage international biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products. Company updates cover R&D and clinical development for cannabinoid-based medicines, medical affairs initiatives, real-world evidence generated through MyMedi.ca, and formulation work involving PwdRx and Rho Phyto. Updates also address regulatory developments affecting medical cannabis research and patient access.
Commercial developments include manufacturing, product launches, exports and partnerships through Avicanna LATAM SAS and Santa Marta Golden Hemp SAS, including Aureus-branded products and CBD wellness topicals. Announcements also report audited financial results, board changes, clinical symposium programming and the expansion of proprietary evidence-based products across medical and pharmaceutical markets.
Avicanna Inc. has issued a correction regarding its previous news release concerning its presentation at the Q1 Virtual Investor Summit. The initial release was dated March 11, 2021, and has now been rendered void. Journalists and readers are advised to disregard it, ensuring that investors and stakeholders have accurate and reliable information regarding the company's activities.
Avicanna (AVCNF) announces CEO Aras Azadian's participation in the upcoming Q1 Virtual Investor Summit from March 23-25, 2021. Azadian's presentation is scheduled for March 24 at 2:00 PM ET. The summit is designed to connect smallcap and microcap companies with over 300 institutional and retail investors, featuring 100 participating companies. Interested investors can register for free at www.investorsummitgroup.com.